Pharma

FDA cites an ‘ongoing review’ for Pfizer’s blockbuster Xeljanz, with implications for the class

On Wednesday a Pfizer representative told Endpoints News that the pharma giant had no immediate plans to take any new actions related to the marketing of their blockbuster drug Xeljanz. But it’s not entirely in their hands.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 50,900+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 50,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->